key: cord-1025939-7d7prsp1
authors: Khuri, Fadlo R.
title: From Cancer to COVID, Boston to Beirut
date: 2021-03-18
journal: Cancer
DOI: 10.1002/cncr.33538
sha: b9d8cdea988df38f632481a0d763c834d1a1b5f6
doc_id: 1025939
cord_uid: 7d7prsp1

The COVID‐19 pandemic has highlighted health and vaccine disparities. Lessons from the collaborative development of targeted therapies for lung cancer and their impact on survival show that there is a better path forward.

Cancer April 15, 2021 I am delighted to announce that the conference itself was in marked contrast to the vaccine wars. Previously undisclosed information, collaborations on the development of new compounds, discoveries and debates about their possibilities and limitations, unpublished data-all were shared openly and collegially. It was a remarkable breath of fresh air at a time when we all badly needed it. The meeting was an example of what can be accomplished when we pool our resources and share our hopes, doubts, and fears. The evidence that this collaborative approach works was there for all to see last summer when an article in The New England Journal of Medicine showed that lung cancer survival has improved since the dawning of targeted therapies for the disease. 1 From Boston to Beirut, the lessons are both evident and abundant, if only we will heed them. We will all do much better when we share knowledge, medicines, and causes.

In his poem "For Whom the Bell Tolls," the great English poet John Donne wrote the following:

No man is an island,

Each is a piece of the continent, A part of the main.

If a clod be washed away by the sea, Europe is the less.

As well as if a promontory were.

Or of thine friend's were.

Each man's death diminishes me, For I am involved in mankind.

Therefore, send not to know For whom the bell tolls, It tolls for thee.

These words are as true today as they were in John Donne's far more challenging era. Cancer, as much as COVID-19, shows us what is possible when we keep the concept of a shared destiny firmly in mind.

No specific funding was disclosed.

The effect of advances in lung-cancer treatment on population mortality

The author made no disclosures.